Pro-inflammatory mediators and transcriptional targets

Pro-inflammatory mediators and transcriptional targets represent a broad functional category of molecules that drive the inflammatory response, rather than a single molecular target. This group includes secreted signaling proteins such as cytokines (e.g., TNF-alpha, IL-1, IL-6) and chemokines, as well as enzymes like cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) (Source: StatPearls, Inflammation, 2023). These mediators are primarily regulated by transcription factors such as Nuclear Factor-kappa B (NF-κB), which translocates to the nucleus to initiate the expression of genes involved in immune activation and cell survival (Source: Nature Reviews Immunology, 2017). In chronic disease states, the persistent production of these mediators leads to tissue destruction and is a hallmark of conditions like rheumatoid arthritis, inflammatory bowel disease, and certain cancers (Source: NIH, National Institute of Allergy and Infectious Diseases). Therapeutic intervention typically involves the use of monoclonal antibodies to neutralize specific cytokines or small molecule inhibitors to block upstream signaling pathways, such as the JAK/STAT or MAPK pathways, thereby preventing the transcription of these inflammatory targets (Source: PubChem, Pharmacology of Anti-inflammatory Agents). Because this term encompasses a wide array of distinct proteins and pathways, it is considered a descriptive grouping of pathological drivers rather than a specific, individual therapeutic target (Source: PubMed, Therapeutic Targeting of Cytokines).

Other names

Inflammatory mediatorsPro-inflammatory gene productsInflammatory cytokines and chemokinesNF-kappaB transcriptional targets

Neutralization of ligands, receptor antagonism, or inhibition of upstream signaling pathways (e.g., NF-kappaB, JAK/STAT, MAPK) to suppress the synthesis and activity of inflammatory proteins.